Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Tang Kevin. Officer active across 4 companies, notably Singular Genomics Systems, Inc.. Aggregated, 41 filings have been published. Breakdown: 40 buys · 0 sell. Total volume traded: €34m. History available since 16 September 2024. The latest transaction was disclosed on 17 July 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Tang Kevin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
TANG KEVIN has 36 filings in total. In the sampled recent filings from 2024-09-18 to 2026-07-16, all transactions are acquisitions, with total purchases of EUR 33482416 and no sales. He is associated with Aurinia Pharmaceuticals Inc. as Chief Executive Officer, with Boundless Bio, Inc. as a 10% Owner, with Fulcrum Therapeutics, Inc. as a 10% Owner, and with Singular Genomics Systems, Inc. with no role listed.